Body adiposity is associated with increased metabolic risk, and evidence indicates that vitamin A is important in regulating body fat. The aim of this study was to evaluate serum concentrations of vitamin A and its association with body adiposity in women with the recommended intake of vitamin A. A cross-sectional study was designed with 200 women divided into four groups according to Body Mass Index (BMI): normal weight (NW), overweight (OW), class I obesity (OI), and class 2 obesity (OII). The cut-off points to assess inadequate participants were retinol < 1.05 µmol/L and β-carotene < 40 µg/dL. Body adiposity was assessed through different parameters and indexes, including waist circumference (WC), waist-to-height ratio (WHtR), hypertriglyceridemic waist (HW), lipid accumulation product (LAP), Visceral Adiposity Index (VAI), and Body Adiposity Index (BAI). It was observed that 55.5% of women had low serum concentrations of β-carotene (34.9 ± 13.8 µmol/L, p < 0.001) and 43.5% had low concentrations of retinol (0.71 ± 0.3 µmol/L, p < 0.001). Women classified as OI and OII had lower mean values of β-carotene (OI—35.9 ± 4.3 µg/dL: OII—32.0 ± 0.9 µg/dL [p < 0.001]). IAV showed significant negative correlation with retinol (r = −0.73, p < 0.001). Vitamin A deficiency is associated with excess body adiposity in women with the recommended intake of vitamin. Greater body adiposity, especially visceral, was correlated with reduced serum concentrations of vitamin A.
Vitamin E (VE) is the main antioxidant of the cell membrane. Research has extensively explored the use of VE in preventing or treating diseases associated with oxidative stress in humans, with a particular emphasis on cardiovascular diseases (CVD). Studies suggest a range of effects beyond its well-established antioxidant action, including anti-inflammatory, immunomodulatory, lipid-lowering, anticoagulant, antidiabetic, and neuroprotective properties. Regarding the effects of VE on the prevention or treatment of CVD and cardiovascular outcomes, the studies showed conflicting results. The benefits of VE were suggested as: (1) the inverse association between increased intake of VE and the risk of stroke, (2) reduced CVD mortality rate, (3) increased glutathione and reduced C-reactive protein, malondialdehyde, LDL, and blood pressure, (4) lower risk of CVD and metabolic syndrome with higher intake of VE, and (5) lower systolic blood pressure. However, a positive association between VE supplementation and diastolic blood pressure was observed. Other adverse effects of VE supplementation have been suggested, such as an increased risk of hemorrhagic stroke and a small but significant increase in the risk of hospitalization in patients with heart failure. Therefore, it is not possible to recommend VE supplementation for the prevention and treatment of CVD.
4 August 2022 in The Journal of Nutritional Biochemistry